NYSE:BMYBristol-Myers Squibb Stock Price, Forecast & News

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BMY shares have increased by 12.6% and is now trading at $63.64.
View which stocks have been most impacted by COVID-19.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bristol-Myers Squibb.

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for Bristol-Myers Squibb.

Bristol-Myers Squibb Co (NYSE:BMY) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.48 by $0.15. The biopharmaceutical company had revenue of $10.13 billion for the quarter, compared to the consensus estimate of $10.04 billion. Bristol-Myers Squibb had a positive return on equity of 28.47% and a negative net margin of 1.61%. The company's revenue was up 61.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.18 EPS.
View Bristol-Myers Squibb's earnings history.

Bristol-Myers Squibb declared a quarterly dividend on Thursday, June 11th. Stockholders of record on Monday, July 6th will be paid a dividend of $0.45 per share on Monday, August 3rd. This represents a $1.80 dividend on an annualized basis and a yield of 2.83%. The ex-dividend date of this dividend is Thursday, July 2nd.
View Bristol-Myers Squibb's dividend history.

Bristol-Myers Squibb issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share (EPS) guidance of $6.10-6.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.22. The company issued revenue guidance of $40.5-42.0 billion, compared to the consensus revenue estimate of $42.00 billion.

16 brokerages have issued 12 month price objectives for Bristol-Myers Squibb's shares. Their forecasts range from $50.00 to $88.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $69.29 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price.
View analysts' price targets for Bristol-Myers Squibb.

Media headlines about BMY stock have been trending very negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about Bristol-Myers Squibb.

Bristol-Myers Squibb saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 21,640,000 shares, a drop of 29.3% from the June 15th total of 30,590,000 shares. Based on an average daily trading volume, of 15,650,000 shares, the short-interest ratio is currently 1.4 days. Approximately 1.3% of the shares of the company are sold short.
View Bristol-Myers Squibb's Short Interest.

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), NVIDIA (NVDA), Verizon Communications (VZ), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), CVS Health (CVS) and Bank of America (BAC).

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Bristol-Myers Squibb's stock is owned by many different institutional and retail investors. Top institutional shareholders include Nordea Investment Management AB (0.87%), Independent Franchise Partners LLP (0.48%), Sumitomo Mitsui Trust Holdings Inc. (0.47%), Swiss National Bank (0.40%), Prudential Financial Inc. (0.24%) and New York State Common Retirement Fund (0.23%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb.

BMY stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, First Trust Advisors LP, Railway Pension Investments Ltd, Sumitomo Mitsui Trust Holdings Inc., State of Tennessee Treasury Department, Senator Investment Group LP, Pzena Investment Management LLC, and New York State Common Retirement Fund. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, John E Elicker, and Louis S Schmukler.
View insider buying and selling activity for Bristol-Myers Squibb.

BMY stock was purchased by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Federated Hermes Inc., AJO LP, Independent Franchise Partners LLP, Laidlaw Wealth Management LLC, Bank of Nova Scotia, Unigestion Holding SA, and Todd Asset Management LLC. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II.
View insider buying and selling activity for Bristol-Myers Squibb.

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BMY stock can currently be purchased for approximately $63.64.

Bristol-Myers Squibb has a market capitalization of $144.00 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

The official website for Bristol-Myers Squibb is www.bms.com.

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]